Maker of inhalable insulin marches on in wake of scrapped IPO
It’s a drug meant for the injection-weary diabetic set: Dance Biopharm‘s developing an inhalable form of insulin, and a series accompanying electric devices to dispense the aerial hormone. It’s slated to go up against MannKind‘s Afrezza. The Bay Area company’s now in the midst of a $15 million debt fundraise, having brought in about $5 million thus […]